GLP-1 Supply-Demand Forecast 2026-2030: When Does Supply Catch Up With Demand?

Three years ago a patient seeking semaglutide had a one in three chance of finding their dose in stock. Today the branded supply has largely caught up. But "caught up" understates what's happening — the entire industry is racing against a demand wave that, when fully unlocked, is at least 5-10x current prescription volume. This is the article we wrote so patients, journalists, and policy people can stop guessing about whether the medication will be available, and start planning around what we actually know.

We update this forecast weekly; the JSON file below carries the actual last-modified date rather than this prose, since a hardcoded date in an article goes stale between edits. The full structured forecast data is available as a machine-readable JSON file — researchers and journalists are welcome to cite or ingest it.

Where we are today (May 2026)

Branded GLP-1 supply has stabilised in the major markets. The FDA removed tirzepatide from its drug shortage list in October 2024 and semaglutide in February 2025. The MHRA, EMA, and other regulators have followed. In day-to-day terms, a US patient with a Wegovy prescription and insurance authorisation can now fill it; a UK patient with a private prescription for Mounjaro can typically obtain it within days; an Indian patient can choose from the generic semaglutide brands our India tracker verifies — 20 brands from 12 manufacturers and co-marketing partners — at roughly 10% of the branded import price.

What this means: the Phase 1 supply crisis (2023-2025) is over for branded medication in supplied markets. It does not mean the market is in equilibrium. Demand at current prices is the demand-at-current-prices number. Demand at $40/month — the Indian generic price — is a different and much larger number. We are early in a multi-year process of supply expansion, generic spread, and demand unlock.

The 2023-2025 shortage in context

The first GLP-1 shortage was in many ways predictable and in some ways not. The predictable part: a single-ingredient injectable medication that became a cultural phenomenon was always going to outrun manufacturing capacity. The unpredictable part: the bottleneck was not the active ingredient.

Both Novo Nordisk and Eli Lilly have substantial active pharmaceutical ingredient (API) capacity. Solid-phase peptide synthesis at industrial scale is mature chemistry. The shortage was driven by fill-finish capacity — the sterile manufacturing step where the bulk peptide is filled into vials or, more critically, into the pre-filled disposable injection pens that patients use. Pen and auto-injector manufacturing requires specialised aseptic lines that take 18-36 months to commission and are similar to the production lines that have served the insulin market for decades.

The shortage taught the industry three things. First, fill-finish is the binding constraint, and the industry-wide pen-line capacity built for diabetes is not enough for a market that includes obesity. Second, demand at any reasonable price elasticity is essentially unbounded — there is no "satiation point" at which addressable demand stops growing. Third, the supply chain is geographically concentrated in a small number of facilities, which makes it vulnerable to a single quality event or regulatory action.

Novo Nordisk's manufacturing response

Novo Nordisk has committed in excess of $20 billion to GLP-1 manufacturing capacity expansion over 2023-2027. The most consequential moves:

Catalent acquisition: In February 2024, Novo Holdings acquired Catalent Inc. for approximately $16.5 billion. Three of the acquired fill-finish sites — in Anagni (Italy), Brussels (Belgium), and Bloomington (Indiana) — were transferred to Novo Nordisk to dedicate to semaglutide. This was the single largest fill-finish capacity addition ever made for a single molecule by a single company.

Kalundborg, Denmark: Continued multi-billion-dollar expansion of the company's home API and fill-finish complex, with new lines coming online progressively through 2025-2027.

Clayton, North Carolina: Multi-billion-dollar expansion of the existing Clayton facility to add fill-finish capacity.

Process intensification: Investments in continuous manufacturing and higher-throughput aseptic lines that yield more doses per unit of facility footprint.

Athlone, Ireland (Monksland site): On 2 March 2026 Novo announced an additional €432 million (approx. DKK 3.2 billion) investment at the Athlone tabletting facility to add oral GLP-1 manufacturing capacity, with Ireland serving markets outside the US. Construction is finalised gradually from end 2027 through 2028, creating up to 500 construction jobs.

The combined effect is that Novo Nordisk's branded semaglutide capacity in 2026 is materially higher than it was in 2023, and the trajectory through 2027 sees further step-changes as the Catalent sites complete their transition and the Athlone oral facility comes online.

Eli Lilly's manufacturing response

Eli Lilly is making the equivalent investment for tirzepatide:

Lebanon, Indiana: Two manufacturing campuses announced — the first in April 2022 ($2.1 billion), a second in May 2024 ($5.3 billion). Combined investment exceeds $9 billion. These are API and fill-finish.

Concord, North Carolina ($1 billion+) and Research Triangle Park, North Carolina (multi-billion): Additional API and fill-finish capacity.

Limerick, Ireland: Expansion of the existing Limerick site for biotech and parenteral manufacturing.

Indianapolis: Expansion of the company's home parenteral manufacturing.

Huntsville, Alabama (API facility): $6 billion facility announced December 9, 2025. Construction is expected to begin in 2026, with completion expected in 2032. Will manufacture active pharmaceutical ingredients for small-molecule and peptide medicines, including orforglipron (Foundayo). Lilly expects 3,000 construction jobs and 450 permanent high-value jobs.

Katwijk, Netherlands (oral medicines facility): $3 billion facility announced November 3, 2025 at Leiden Bio Science Park. Construction is expected to begin in 2026, and the investment is contingent on government permits and local approvals; Lilly has not given a production-start date. The site will make oral solid medicines across cardiometabolic health, neuroscience, oncology and immunology, and will be among the sites manufacturing orforglipron; Lilly frames it as serving patients worldwide. Lilly expects 500 manufacturing jobs and an estimated 1,500 construction jobs.

Lehigh Valley, Pennsylvania (injectable medicine and device facility): more than $3.5 billion, announced January 30, 2026, to produce next-generation weight-loss therapies including retatrutide. Lilly says the site will bring 850 jobs and be operational in 2031.

By 2027 Lilly's tirzepatide manufacturing capacity is forecast to support the company's "many millions of patients globally" stated ambition. Total committed US manufacturing investment now exceeds $27 billion; the global total including Netherlands and other international sites is higher.

The generic capacity question

While Novo and Lilly build branded capacity, an entirely separate manufacturing base is coming online for generic semaglutide outside the OECD patent zone:

India: Following the March 20, 2026 patent expiry, the first CDSCO-approved generic was on pharmacy shelves within 48 hours (Natco, first to market); within three weeks, press tracking counted roughly 15 manufacturers and licensing partners on the market, at prices up to 90% below branded. Press counts published on 20 March 2026 expected more than 50 brand names from over 40 manufacturers across the market through 2026, and a trade list the same month enumerated 52 generic brand names lined up for launch — both are entry expectations, not counts of approvals granted or products launched; the approvals those sources name are a handful (Sun Pharma December 2025, Natco February 2026, Dr Reddy's), described as the first wave of formal regulatory entries ahead of broader launches. Our India tracker verifies 20 generic brands from 12 manufacturers and co-marketing partners, including Dr Reddy's (Obeda), Natco (Semanat, Semafull), Sun Pharma (Noveltreat, Sematrinity), Glenmark (GLIPIQ), Zydus (Semaglyn, Mashema, Alterme), Eris with Natco (Sundae), Alkem, Mankind, Torrent, MSN and USV — Lupin co-markets Zydus's licensed product rather than manufacturing independently. Note: Dr Reddy's (Obeda) paused commercial semaglutide supply in July 2026 after finished-product batches tested out of specification for an API-derived impurity; on its 9 July 2026 investor call (SEC 6-K) the company said supply could resume around late October or early November and that it hoped to supply 6-7 million pens across Q3 and Q4 of FY27 (October 2026 to March 2027) — a fiscal-year target, not a resumption volume. Which other Indian brands share Dr Reddy's supply is not stated (our tracker lists USV's Usema as co-marketed with Dr Reddy's); an earlier same-day version claimed the other brands were unaffected, which no source supports (corrected 2026-09-27). Indian peptide manufacturing capacity is large and scalable. Our own conservative estimate — a Magistra projection derived from announced manufacturer and brand counts, not an independently sourced figure — puts combined Indian generic capacity at 10-30 million patient-years annually within 18-24 months of launch — far in excess of current Indian domestic demand, with significant export capability to other patent-expired markets.

China: Domestic semaglutide applications are in the NMPA review queue. The South China Morning Post (27 March 2026) names Hangzhou Jiuyuan Gene Engineering (Jikeqin, accepted for review 25 February 2026), Livzon, Qilu Pharmaceutical, Fosun Wanbang, Huadong Medicine, CSPC and Chengdu Brilliant; a Chinese industry summary (Tonacea, 20 March 2026) counts ten accepted semaglutide biosimilar applications by the end of 2025, adding United Laboratories, Huisheng Biologics and Chia Tai Tianqing, with "nearly 20 more biosimilars" in clinical stages. As of late September 2026 we have found no evidence that any domestic generic has been approved and brought to market. (Corrected 2026-09-27: an earlier same-day edit attributed nine names and "8 more in Phase 3" to SCMP, September 2026; SCMP's article is dated 27 March 2026, names seven companies and gives no Phase 3 count.) China is in the unusual position of being both a large potential domestic market and a peptide manufacturing powerhouse.

Brazil: ANVISA has registered at least ten semaglutide products since the March 2026 patent expiry. Brazilian capacity primarily serves the domestic market. Note: every semaglutide registered in Brazil before Ozivy was a biological product, so ANVISA registered Ozivy as a new drug (a synthetic analogue), not a generic. The first synthetic semaglutide pen, Ozivy (EMS SA), was registered by ANVISA on 26 May 2026 and went on sale from 15 June 2026 at a launch price of R$452 per pen for the 0.25/0.5 mg starter pen (R$498 per 1 mg maintenance pen; about R$287/month for the first three months on EMS's Vida Mais Leve programme) — T2D indication. Corrected 24 September 2026: this sentence previously gave R$452 as a monthly price. EMS says its plant in Hortolândia (São Paulo state) can make up to 40 million pens a year (Forbes Brasil, June 2026). On July 29, 2026, ANVISA registered five more in a single day (Owozy, Seemasun, Zempneo, Semavy, Orsema), and on August 17, 2026 two more (an EMS generic and Germed's Semaclique); a Germed generic was published in the Diário Oficial on 24 August 2026, and EMS's Yluméc on 31 August 2026. Pharmacy sale also needs a CMED (Brazil's price authority) price ceiling: Hypera's Semavy cleared CMED (announced 10 August 2026) and went on sale on 4 September 2026; we have not verified CMED status for the rest.

Canada: Four generics approved as of 18 September 2026. Dr. Reddy's received Health Canada approval April 28, 2026 (T2D); Apotex received approval May 1, 2026 (T2D, first Canadian-based company) and commercially launched Apo-Semaglutide Injection on May 14, 2026; Apotex received a third approval on June 29, 2026 for Sevmia (semaglutide injection) for chronic weight management in patients 12 and older — the first generic semaglutide for weight management approved in Canada, and in any G7 country. On September 18, 2026, Sandoz announced Health Canada authorization for Sandoz Semaglutide, a generic of Ozempic for type 2 diabetes, with no launch date given. On June 29, 2026 Health Canada said it was reviewing six other generic semaglutide submissions; it has published no later count. Mexico: In regulatory review at COFEPRIS; launch expected 2026-2027.

This generic capacity is not currently legally exportable to the United States, EU, UK, Japan, or Australia, where the composition patent runs to approximately 2031. It is, however, exportable between patent-expired jurisdictions — so Indian generic capacity can serve Brazilian and Canadian markets, where patents have lapsed.

The demand picture is shifting structurally

The supply story is dramatic, but the demand story is the larger force. GLP-1 demand was growing from a weight-loss starting point. It is now expanding into multiple co-morbidity indications, each of which can substantially expand the addressable patient population:

Cardiovascular outcomes: The SELECT trial (Lincoff et al., NEJM November 2023) showed semaglutide 2.4mg reduced major adverse cardiovascular events by 20% in non-diabetic patients with established cardiovascular disease and overweight/obesity. The FDA approved a cardiovascular indication for Wegovy in March 2024. This unlocked broader insurance coverage in the US — many commercial plans that previously excluded weight-loss now cover Wegovy on cardiovascular grounds.

Cardiovascular outcomes — tirzepatide (Mounjaro): The SURPASS-CVOT trial (13,299 adults with type 2 diabetes and established cardiovascular disease, median observation 210 weeks), head-to-head against Trulicity (dulaglutide 1.5mg, itself a drug with a cardiovascular indication), showed tirzepatide non-inferior for MACE-3: 12.1% vs 13.0%, HR 0.92 (95.3% CI: 0.83–1.01). Superiority over dulaglutide was not established. The FDA approved Mounjaro on August 28, 2026 to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events (current label, section 1 and 14.6) — the first dual GIP/GLP-1 receptor agonist to carry a cardiovascular indication. This adds a cardiovascular reimbursement route for Mounjaro in type 2 diabetes.

Chronic kidney disease: The FLOW trial (Perkovic et al., NEJM 2024) showed semaglutide reduced kidney disease progression and cardiovascular death in T2D patients with CKD. This expands the diabetes-with-CKD patient pool and provides another reimbursement vector.

Obstructive sleep apnea: The SURMOUNT-OSA trial (Malhotra et al., NEJM 2024) showed tirzepatide significantly reduced sleep apnea severity. The FDA approved Zepbound for moderate-to-severe OSA in adults with obesity in December 2024. Sleep apnea is reimbursed by most insurance.

Heart failure with preserved ejection fraction (HFpEF): The STEP-HFpEF trial showed semaglutide improved heart failure symptoms and exercise capacity in obese HFpEF patients. Label expansion likely.

Alcohol use disorder: Multiple Phase 2 readouts suggest GLP-1 medications may reduce alcohol consumption. Larger trials are underway.

Alzheimer's disease (EVOKE/EVOKE+ — NEGATIVE): The Phase 3 EVOKE and EVOKE+ trials of oral semaglutide in 3,808 early-stage Alzheimer's patients found no significant slowing of disease progression versus placebo at 2 years: the change in CDR-SB score at week 104 did not differ from placebo in either trial (p=0.57 in EVOKE, p=0.46 in EVOKE+). Published in The Lancet, March 19, 2026 (PMID 41865758). This indication is closed for semaglutide. Residual interest in GLP-1 mechanism for neuroinflammation at earlier disease stages remains hypothesis-generating only.

Liver disease (MASH): Semaglutide (Wegovy 2.4mg) FDA approved August 2025 for non-cirrhotic MASH with F2-F3 fibrosis — ESSENCE Phase 3 (week-72 interim analysis, first 800 patients): 62.9% vs 34.3% placebo achieved steatohepatitis resolution without worsening of fibrosis; 36.8% vs 22.4% achieved fibrosis improvement without worsening of steatohepatitis (NEJM 2025, PMID 40305708). Tirzepatide is not FDA-approved for MASH: the current Zepbound label lists weight management and obstructive sleep apnoea only. Its MASH evidence is the Phase 2 SYNERGY-NASH trial (190 participants, 52 weeks), in which 62% on 15 mg vs 10% on placebo achieved MASH resolution without worsening of fibrosis (NEJM 2024, PMID 38856224). The semaglutide approval adds a patient pool and a new insurance reimbursement route.

Every successful trial adds patients to the addressable pool and adds reimbursement vectors that expand access.

The oral GLP-1 wave (two products now on the US market)

Before the April 2026 Foundayo launch, another oral GLP-1 had already entered the US market. Novo Nordisk's Wegovy pill (oral semaglutide 25mg) was FDA approved on December 22, 2025 — making it the first oral GLP-1 approved specifically for weight management in the United States — and launched broadly in US pharmacies from January 5, 2026. The OASIS 4 trial showed 16.6% mean weight loss when treatment was adhered to (Novo's trial-product estimand). Self-pay pricing: $149/month for the 1.5mg starting dose; $199/month for the 4mg dose (effective September 1, 2026); $299/month for maintenance doses (9mg and 25mg); commercial insurance copay as low as $25/month with Novo's savings card. Novo's Q1 2026 results (reported May 6, 2026) showed oral Wegovy sales of DKK 2,256 million in its first quarter, a figure Novo says was boosted by pre-launch pipeline fill with wholesalers and telehealth partners, on around 1.3 million prescriptions. Novo called it the strongest-ever GLP-1 volume launch in the US. By early June 2026, Novo announced that oral Wegovy had surpassed 3 million total prescriptions — approximately one prescription filled every five seconds. In that release, 82% of new-to-brand starts (IQVIA, 9 Jan to 15 May 2026) were in people with no other GLP-1 medicine in the prior 12 months, compounded products not counted (Novo ADA announcement, June 7, 2026). In Q2 2026 oral Wegovy took DKK 3,141 million in US sales on around 2.9 million prescriptions, and by the time of Novo's Q2 report of August 4, 2026 the total since launch had passed 5 million US prescriptions (above 265,000 a week in the week ending July 17, 2026). The same report says the UK launch in early July is "early days" with "encouraging" initial sales, and gives no UK patient count. Separately, Novo announced a €432 million investment in its Athlone, Ireland tabletting facility (2 March 2026) to add oral GLP-1 capacity for markets outside the US, finalised gradually from end 2027 through 2028.

At its 18-21 May 2026 meeting (announced 22 May), the EMA's CHMP adopted a positive opinion recommending the Wegovy pill (oral semaglutide 25mg) be added to Wegovy's EU marketing authorisation — the first oral GLP-1 recommended for EU weight management. CHMP also recommended approval of the Wegovy 7.2mg single-dose pen (STEP UP trial: 20.7% mean weight loss in adults with obesity; STEP UP T2D: 14.1%; both on Novo's efficacy estimand, i.e. had everyone stayed on treatment). On July 14, 2026, the European Commission extended Wegovy's EU marketing authorisation (Commission Implementing Decision C(2026) 5102) to add both the Wegovy pill (oral semaglutide tablets, 1.5mg to 25mg) and the Wegovy 7.2mg single-dose pen, valid across all EU member states.

Ahead of the EU formal decision, the MHRA approved the Wegovy pill (oral semaglutide tablets, 1.5mg to 25mg) for weight management in the United Kingdom on 11 June 2026 — about five weeks before the European Commission's 14 July 2026 decision. The approved indication covers adults with initial BMI ≥30 kg/m², or ≥27 kg/m² with a weight-related comorbidity. In the OASIS 4 trial of oral semaglutide 25mg (NEJM 2025, PMID 40934115), mean weight change at 64 weeks was −13.6% versus −2.2% for placebo. Approved dosing steps: 1.5mg → 4mg → 9mg → 25mg. The UK private launch followed in July 2026, with advertised prices from £99/month (1.5mg starting dose) up to £269/month depending on dose and provider, and the 25mg maintenance dose from £170/month (medino comparison, updated 18 September 2026); NICE lists its oral semaglutide obesity appraisal (ID6188) as discontinued since 12 May 2025, after the company told NICE it would not provide an evidence submission, so NICE has made no recommendation on it.

On 10 August 2026, the MHRA approved Foundayo (orforglipron) in the UK — making the UK the first country in Europe to authorise orforglipron. The approved indications cover both weight management (adults with BMI ≥30, or ≥27 with a weight-related comorbidity) and type 2 diabetes. Foundayo is a once-daily oral small-molecule GLP-1 agonist with no food or water restrictions (unlike oral semaglutide). In the ATTAIN-1 trial, 11.2% mean weight loss at 72 weeks on the highest trial dose (36 mg), vs 2.1% on placebo (treatment-regimen estimand; Wharton et al., NEJM 2025). Lilly launched it for private prescription on 24 August 2026 and said it would likely be priced between £100 and £120 a month (Reuters, 24 Aug 2026); NICE's appraisal (ID6516) is in progress: its committee met on 14 July 2026, could not reach a full conclusion because more information is needed from the company; NICE's provisional expected publication date is 18 November 2026.

On 15 October 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Foundayo (orforglipron) at its 12–15 October 2026 meeting, recommending EU marketing authorisation for both type 2 diabetes and weight management. EMA gives no decision date; the European Commission usually decides within about 67 days of a CHMP opinion, which would put a decision around December 2026 (our estimate). This follows the UK MHRA approval of 10 August 2026.

Eli Lilly's orforglipron (Foundayo) — a small-molecule oral GLP-1 agonist, chemically distinct from peptide GLP-1s like semaglutide and tirzepatide — was FDA approved on April 1, 2026 for weight management in adults with obesity or overweight with a weight-related condition. Its US label carries no type 2 diabetes or cardiovascular indication (the UK approval below does include type 2 diabetes). The supply-side implications this article previously forecast as conditional are now confirmed:

Manufacturing: Small-molecule oral medication is dramatically cheaper to manufacture than peptide injectables. The fill-finish bottleneck disappears entirely.

Distribution: Tablets do not require cold chain. They can be shipped through normal pharmacy supply chains globally.

Capacity expansion: Small-molecule capacity can be added much faster than peptide aseptic capacity.

Patient access: No injection barrier, no cold-chain barrier, much simpler prescription fulfilment.

Foundayo is sold at self-pay pricing of $149/month (0.8 and 2.5 mg) to $299/month (9-17.2 mg) via LillyDirect, with 5.5 mg at $199; the 2.5 and 5.5 mg prices are temporary reductions through 31 December 2026, and the 14.5/17.2 mg price requires each refill within 45 days (otherwise $349). significantly below Wegovy's $1,349/month list. Commercial insurance copays as low as $25/month with Lilly's savings card. Under standard Medicare Part D, Foundayo is covered for its Part D-eligible indications (T2D, cardiovascular risk reduction) at whatever cost sharing the beneficiary's own plan sets — not at a flat $50. The $50 figure belongs to the separate Medicare GLP-1 Bridge (from 1 July 2026), which covers the weight-management use only and expressly excludes beneficiaries who have a Part D-eligible diagnosis. This is the most material cost-reduction event for US patients since the 2023-2025 shortage resolved — a legal, oral, branded GLP-1 option at a fraction of injectable branded prices.

New molecules in late-stage development

Beyond the marketed semaglutide, tirzepatide, and liraglutide, several next-generation molecules are in late-stage development:

Retatrutide (Eli Lilly): Triple agonist (GIP/GLP-1/glucagon). Phase 3 (TRIUMPH programme, multiple trials reading out 2026). TRIUMPH-1 (pivotal registrational obesity trial, topline May 21, 2026; full data presented at ADA 86th Scientific Sessions, June 2026): 28.3% mean body weight loss at 80 weeks on 12mg (vs 2.2% placebo; efficacy estimand — 25.0% vs 3.9% counting all randomised participants) in 2,339 non-diabetic adults with obesity or overweight and at least one comorbidity; 30.3% at 104 weeks in a pre-specified extension for participants with baseline BMI≥35 who continued on 12mg (85 lbs average); 45.3% of 12mg participants achieved ≥30% body weight loss — a threshold long associated with bariatric surgery outcomes. All doses met primary and key secondary endpoints. ADA 2026 sleep apnea basket (nested within TRIUMPH-1): retatrutide reduced the apnea-hypopnea index by up to 60.6% (up to 36.1 fewer breathing events per hour, from a baseline of 58.6) in participants with moderate-to-severe obstructive sleep apnea (best-performing dose; efficacy estimand). TRIUMPH-4 (obesity + knee osteoarthritis; topline December 11, 2025): 28.7% mean weight loss at 68 weeks on 12mg (vs 2.1% placebo); WOMAC knee-pain scores fell 75.8% on 9mg and 74.3% on 12mg (vs 40.3% placebo); new safety signal: dysesthesia in 20.9% at 12mg and 8.8% at 9mg vs 0.7% placebo, characterised by Lilly as generally mild and rarely leading to discontinuation. On July 23, 2026, Lilly announced that TRIUMPH-2 (adults with obesity or overweight and type 2 diabetes) and TRIUMPH-3 (adults with severe obesity and established cardiovascular disease) both met their primary endpoints — TRIUMPH-3 showed 22.6% mean weight loss at 80 weeks on 12 mg (55.8 lbs average; vs 3.2% placebo; efficacy estimand, i.e. had everyone stayed on treatment). TRIUMPH-2 showed 20.8% mean weight loss at 80 weeks on 12 mg (vs 4.0% placebo; efficacy estimand), with A1C reductions of up to an average of 1.6%. Adverse events led 7.7% of 12 mg participants to stop treatment in TRIUMPH-2 (vs 4.9% on placebo) and 13.5% in TRIUMPH-3 (vs 4.8%). Lilly plans to submit a Biologics License Application (BLA) in Q1 2027, after completing the manufacturing (CMC) data package a BLA requires; on standard FDA review timelines a decision would fall in late 2027-2028 (our estimate, not Lilly's). That BLA plan rests on a pending classification dispute: FDA ruled retatrutide is not a biologic (it counts fewer than the 40+ alpha amino acids its protein definition requires; Lilly counts 41), which would mean an NDA with 5-year exclusivity rather than a BLA with 12; on 30 September 2025 the US District Court for the Southern District of Indiana upheld FDA's finding that retatrutide is not a "protein", but vacated as arbitrary and capricious FDA's refusal to treat it as "analogous" to a protein and sent that question back to FDA; Lilly has appealed to the Seventh Circuit, and as of 5 August 2026 BioSpace reported the litigation unresolved. The outcome is economically material, as BLA classification would significantly extend the pre-biosimilar window (sources: court docket, Eli Lilly and Company v. Kennedy, S.D. Ind. 1:24-cv-01503; biospace.com August 5, 2026; news.bloomberglaw.com October 1, 2025).

Survodutide (Boehringer Ingelheim / Zealand Pharma): Dual GLP-1/glucagon agonist. Phase 3 (SYNCHRONIZE programme; first two trials reported at ADA 86th Scientific Sessions, June 2026). SYNCHRONIZE-1 (725 adults with obesity or overweight, without type 2 diabetes; 76 weeks; published NEJM at ADA 2026): mean weight loss of up to 16.6% from baseline (efficacy estimand) versus 3.2% on placebo. In an MRI sub-study, visceral fat fell by up to 34% and liver fat by up to 63.1%, with lean mass no more than 10.8% of the change in total tissue mass at the highest dose. 19% of survodutide participants stopped treatment because of gastrointestinal side effects, versus 2.9% on placebo. SYNCHRONIZE-MASLD (separate 48-week trial, 218 adults with obesity or overweight and metabolic dysfunction-associated steatotic liver disease; published Nature Medicine at ADA 2026) met both primary endpoints: up to 84.2% reached at least a 30% relative liver fat reduction (vs 24.3% placebo) and body weight fell up to 12.2% (vs 1.0%). In a secondary endpoint, up to 61.0% reached liver fat normalisation (vs 5.7%). Neither the April nor the June release gave a regulatory submission timeline.

Cagrisema (Novo Nordisk): Combination of cagrilintide and semaglutide. Submitted to the US FDA for weight management in December 2025. REDEFINE 1 showed 20.4% mean weight loss at 68 weeks (vs 3.0% placebo; NEJM 2025). The open-label REDEFINE 4 head-to-head trial (reported February 23, 2026) did not meet its primary endpoint of non-inferiority to tirzepatide 15mg: 23.0% vs 25.5% weight loss at 84 weeks (809 participants); Novo's Q1 2026 report restates that the primary endpoint was not achieved. BioCentury wrote that CagriSema's commercial prospects "dim further" after the miss.

MariTide (Amgen): Phase 3.

CT-388 (Roche, formerly Carmot): Dual GLP-1/GIP agonist. Phase 2 readouts strong.

Pfizer's danuglipron programme was discontinued in 2025 after liver enzyme elevations and other safety signals — a useful reminder that not every late-stage candidate reaches market.

The 2026-2030 supply-demand projection

The forecast we maintain has the following directional shape:

These ranges are wide on purpose — addressable demand depends heavily on what fraction of the global obesity and obesity-related comorbidity population gets prescribed and reimbursed. The structural pattern is:

Branded supply growth is roughly linear and forecastable (capex is mostly committed).

Generic supply growth in patent-expired markets is faster than linear (low capex per added unit, multiple competitive entrants).

Demand growth is non-linear and depends on policy switches — particularly US Medicare coverage of anti-obesity medication, which Magistra estimates (not independently sourced; see the policy section below for the basis) could add on the order of 50-100 million eligible patients in the US alone.

Three scenarios for when supply meets unlocked demand:

Bull case (supply abundant by 2028): Combined branded + Indian generic capacity ramps faster than expected; orforglipron approves; OECD demand stays gated by insurance. In this scenario branded prices begin to soften before 2031 patent expiry.

Base case (supply meets demand around 2030-2032): Branded capacity continues steady growth; generic Indian capacity scales but remains regional; orforglipron approves and modestly expands access; 2031 OECD generic wave is the inflection.

Bear case (chronic constraint through mid-2030s): US Medicare coverage unlocks; major emerging-market reimbursement (China, Brazil) expands; demand unlock outpaces supply; chronic shortages return in the late 2020s.

Magistra's central case is closer to the base case, with non-trivial probability on the bull case. We do not currently see the bear case as the most likely path, but it would only require one or two demand-unlock policy events to become so.

The 2031 OECD generic wave

The single most important date on the GLP-1 supply-demand calendar is approximately 2031, when the semaglutide composition patent lapses in the United States, EU, UK, Japan, and Australia. Generic supply ramping to serve the largest pharmaceutical markets in the world will reset prices in those markets to roughly 10-20% of branded — the same compression already visible in India.

The 2031 wave will:

Crash branded prices: Novo Nordisk and Eli Lilly have already factored this into their long-range planning. Analyst forecasts assume material price pressure on Wegovy and Ozempic from 2031.

Unlock insurance reimbursement: Insurers that exclude branded weight-loss medication today will reconsider when generic prices make the cost-benefit dramatically different.

Compress the addressable demand curve into actual demand: Many patients who want the medication today but cannot afford it will be able to fill prescriptions.

Pressure Eli Lilly's tirzepatide pricing: Tirzepatide patents extend approximately 5 years beyond semaglutide. Lilly's premium pricing for tirzepatide will be tested as patients have a generic semaglutide alternative at a fraction of the cost. Two pairs of Paragraph IV ANDA challenges have already been filed since the NCE-1 date of May 13, 2026 — Sandoz (acceptance announced June 29, 2026) and Amneal/Adalvo (acceptance announced July 8, 2026) — though final approval cannot come before ~2036 absent successful litigation.

This is the single largest economic event in the GLP-1 medication ecosystem for the rest of the decade.

What this means for patients

A patient making a treatment decision in 2026 should plan around the following:

Branded supply is no longer a constraint in the US, UK, EU and most major markets. If you have a prescription and can afford the medication (insurance or out-of-pocket), it is available.

Affordability is now the binding constraint, not supply. The 2023-2025 question was "can I get any?". The 2026-2030 question is "can I afford to keep taking it?".

If you are in India: generic semaglutide at roughly 10% of branded price is your near-certainty path. Use it. If you are in Brazil or another patent-expired market: generic or analogue options exist, but we do not publish a generic-vs-branded price ratio for them — check current prices before assuming a similar saving (see our GLP-1 Economics page for the Brazil price table).

If you are in the US, UK, or EU and considering long-term therapy: the cost picture improves materially in 2031. If you are stable on your current dose and reimbursed, plan around the lifelong-usage assumption (see our GLP-1 Economics page for 10-year cost scenarios).

Orforglipron (Foundayo) is approved as of April 2026: at $149-299/month self-pay it is among the cheapest branded GLP-1s in the US, tied with Novo’s Wegovy pill, which this site records at the same $149-299/month self-pay range (corrected 2026-09-20: this previously claimed it was “the most affordable”, a superlative our own pricing table does not support). For patients who prefer oral over injectable, this is available now — no waiting for 2031.

The supply scenario most worth planning around is base case, not bear case: chronic shortages are unlikely to return through the late 2020s, but a major demand-unlock event (US Medicare coverage being the most consequential) would change that.

What this means for policymakers

The GLP-1 supply-demand picture is a near-textbook case of a medication where access is gated by patent geography rather than physical scarcity. The policy levers that would change the access picture most:

US Medicare coverage of anti-obesity medication: Starting July 1, 2026, a temporary Medicare GLP-1 Bridge Program (through December 31, 2027) gives eligible Part D beneficiaries Foundayo, Wegovy (injection and tablets) or Zepbound (KwikPen only) for the weight-management use at a $50 copay per monthly supply. It is a CMS Section 402 demonstration, not an Innovation Center model, and it is narrower than the headline: a prescriber-attested prior authorization is mandatory; CMS's criteria run in three tiers (BMI ≥35; or ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension or chronic kidney disease stage 3a+; or ≥27 with pre-diabetes, previous myocardial infarction, previous stroke or symptomatic peripheral artery disease); and beneficiaries who have a Part D-eligible diagnosis (type 2 diabetes, moderate-to-severe obstructive sleep apnoea, noncirrhotic MASH, or cardiovascular risk reduction in established CVD) are expressly ineligible and use their Part D plan instead. Participating manufacturers supply at a net price of $245 per monthly supply. This is a significant but temporary partial unlock: it does not change the underlying statutory prohibition (Section 1860D-2(e)(2)(A)) and expires unless further extended. Full statutory coverage via the Treat and Reduce Obesity Act (TROA, re-introduced in every Congress since 2013; current version H.R.4231/S.1973) remains the largest potential demand unlock globally. Magistra estimate, not independently sourced: on the order of 50-100 million eligible US patients on a permanent basis.

Compulsory licensing in middle-income countries: Brazil and India have used this mechanism for other medicines. It is legally available for GLP-1 outside the patent zone but politically rarely invoked.

Patent term extensions and evergreening: Novo Nordisk and Eli Lilly have a clear interest in extending patent protection through formulation and combination patents. Watching the formal patent challenges in major markets is part of any serious supply forecast.

Speeding generic regulatory pathways: jurisdictions that streamline ANDA-equivalent processes for biosimilars and complex generics will see faster supply arrival post-2031.

WHO Essential Medicines List (September 2025) + WHO obesity guideline (December 2025): On 5 September 2025, WHO added semaglutide, dulaglutide, liraglutide and tirzepatide to the WHO Model Essential Medicines List as glucose-lowering therapy for adults with type 2 diabetes who also have established cardiovascular or chronic kidney disease and obesity (BMI ≥ 30). On 1 December 2025, WHO issued a separate global guideline with conditional recommendations that GLP-1 therapies (liraglutide, semaglutide, tirzepatide) may be used for the long-term treatment of obesity in adults, excluding pregnant women, as part of comprehensive care. WHO projects these medicines will reach fewer than 10% of those who could benefit by 2030 and calls for pooled procurement, tiered pricing and voluntary licensing to widen access. Neither step lowers prices or mandates reimbursement by itself; how fast national procurement responds is the thing to watch.

Methodology and data sources

This forecast synthesises:

Manufacturer earnings calls and investor day presentations (Novo Nordisk Q4 2024 and FY2025; Eli Lilly Q4 2024 and FY2025; investor day materials)

Capacity expansion announcements (Catalent acquisition press materials; Lebanon IN announcements; Kalundborg expansion details)

Regulatory filings (FDA shortage list, EMA notices, MHRA bulletins, CDSCO India approvals)

Public clinical trial readouts (SELECT, FLOW, SURMOUNT-OSA, EVOKE and others, all referenced via the New England Journal of Medicine, JAMA, or trial registry)

Sell-side analyst market-sizing estimates for the GLP-1 category. These diverge more than a single range implies: several banks cluster around $130-200 billion for 2030, but at least one major bank publicly revised its estimate down to under $100 billion in 2025, citing patient discontinuation rates and pricing pressure as reasons the market could undershoot the bull case. We report the spread, not a single consensus figure, because there isn't one.

Indian generic capacity tracking from manufacturer announcements and regulatory filings (CDSCO approvals, company press releases)

We update this forecast weekly. Material revisions trigger a dated change-log entry in the structured JSON dataset at `/data/glp1-supply-demand-forecast.json`. Researchers, journalists, and policy analysts are welcome to cite this work; please use the citation format on our GLP-1 Economics page.

---

Magistra Health publishes evidence-based information for patients, physicians, and decision-makers in the GLP-1 ecosystem. This article is part of our GLP-1 Economics hub, which is designed to be the most comprehensive single source on GLP-1 medication economics on the internet. Updated weekly.

Magistra is not a financial advisor and does not make investment recommendations. The forecast presented here reflects our best reading of public information as of the publication date. Actual outcomes will differ. Magistra does not provide medical advice. If you are considering a GLP-1 medication, please consult a licensed healthcare provider.